Compile Data Set for Download or QSAR
Report error Found 447 Enz. Inhib. hit(s) with all data for entry = 12207
TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611539(CHEMBL5275211 | US20240246937, Example 1)
Affinity DataEC50:  10nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686556(US20240246937, Example 2)
Affinity DataEC50:  9nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686557(US20240246937, Example 3)
Affinity DataEC50:  12nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686558(US20240246937, Example 4)
Affinity DataEC50:  19nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686559(US20240246937, Example 5)
Affinity DataEC50:  50nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686560(US20240246937, Example 6)
Affinity DataEC50:  43nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686561(US20240246937, Example 7)
Affinity DataEC50:  9nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686562(US20240246937, Example 8)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686563(US20240246937, Example 9)
Affinity DataEC50:  15nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686564(US20240246937, Example 10)
Affinity DataEC50:  21nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686565(US20240246937, Example 11)
Affinity DataEC50:  16nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686566(US20240246937, Example 80 | US20240246937, Example...)
Affinity DataEC50:  8nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686567(US20240246937, Example 13)
Affinity DataEC50:  8nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611540(CHEMBL5277779 | US20240246937, Example 14)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686569(US20240246937, Example 15)
Affinity DataEC50:  44nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686570(US20240246937, Example 16)
Affinity DataEC50:  16nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686571(US20240246937, Example 17)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686572(US20240246937, Example 18)
Affinity DataEC50:  41nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686573(US20240246937, Example 19)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686574(US20240246937, Example 20)
Affinity DataEC50:  5nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686575(US20240246937, Example 21)
Affinity DataEC50:  14nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686576(US20240246937, Example 22)
Affinity DataEC50:  22nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686577(US20240246937, Example 23)
Affinity DataEC50:  21nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686578(US20240246937, Example 24)
Affinity DataEC50:  30nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686579(US20240246937, Example 25)
Affinity DataEC50:  21nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686580(US20240246937, Example 26)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611541(CHEMBL5269844 | US20240246937, Example 27)
Affinity DataEC50:  5nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686582(US20240246937, Example 28)
Affinity DataEC50:  8nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686583(US20240246937, Example 29)
Affinity DataEC50:  9nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686584(US20240246937, Example 30)
Affinity DataEC50:  8nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686585(US20240246937, Example 31)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686586(US20240246937, Example 32)
Affinity DataEC50:  5nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686587(US20240246937, Example 33)
Affinity DataEC50:  8nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686588(US20240246937, Example 34)
Affinity DataEC50:  34nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686589(US20240246937, Example 35)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686590(US20240246937, Example 36)
Affinity DataEC50:  6nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686591(US20240246937, Example 37)
Affinity DataEC50:  18nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611542(CHEMBL5267809 | US20240246937, Example 38)
Affinity DataEC50:  23nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686593(US20240246937, Example 39)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686594(US20240246937, Example 41 | US20240246937, Example...)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686594(US20240246937, Example 41 | US20240246937, Example...)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686596(US20240246937, Example 42)
Affinity DataEC50:  5nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686597(US20240246937, Example 43)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686598(US20240246937, Example 44)
Affinity DataEC50:  7nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686599(US20240246937, Example 45)
Affinity DataEC50:  5nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686600(US20240246937, Example 46)
Affinity DataEC50:  13nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686601(US20240246937, Example 47)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611543(CHEMBL5267902 | US20240246937, Example 48)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686603(US20240246937, Example 49)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686604(US20240246937, Example 50)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 447 total ) | Next | Last >>
Jump to: